Patents Assigned to Ventus Therapeutics U.S., Inc.
  • Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
    Patent number: 11618751
    Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein.
    Type: Grant
    Filed: March 25, 2022
    Date of Patent: April 4, 2023
    Assignee: Ventus Therapeutics U.S., Inc.
    Inventor: Stéphane Dorich
  • Compounds for inhibiting NLRP3 and uses thereof
    Patent number: 11319319
    Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: May 3, 2022
    Assignee: Ventus Therapeutics U.S., Inc.
    Inventors: Stéphane Dorich, Amandine Chefson, Alexandre C{hacek over (o)}té